We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed the most recent trading day at $1,027.51, moving +1.8% from the previous trading session. This change outpaced the S&P 500's 1.07% loss on the day. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq lost 1.69%.
Coming into today, shares of the drugmaker had lost 1.32% in the past month. In that same time, the Medical sector gained 2.1%, while the S&P 500 gained 0.94%.
Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company is forecasted to report an EPS of $7.5, showcasing a 40.98% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $18.16 billion, up 34.2% from the prior-year quarter.
LLY's full-year Zacks Consensus Estimates are calling for earnings of $23.91 per share and revenue of $63.97 billion. These results would represent year-over-year changes of +84.06% and +42.02%, respectively.
Any recent changes to analyst estimates for Eli Lilly should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.6% higher. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is presently being traded at a Forward P/E ratio of 42.22. This valuation marks a premium compared to its industry average Forward P/E of 14.09.
We can also see that LLY currently has a PEG ratio of 1.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.6 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 185, finds itself in the bottom 26% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Eli Lilly (LLY - Free Report) closed the most recent trading day at $1,027.51, moving +1.8% from the previous trading session. This change outpaced the S&P 500's 1.07% loss on the day. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq lost 1.69%.
Coming into today, shares of the drugmaker had lost 1.32% in the past month. In that same time, the Medical sector gained 2.1%, while the S&P 500 gained 0.94%.
Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company is forecasted to report an EPS of $7.5, showcasing a 40.98% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $18.16 billion, up 34.2% from the prior-year quarter.
LLY's full-year Zacks Consensus Estimates are calling for earnings of $23.91 per share and revenue of $63.97 billion. These results would represent year-over-year changes of +84.06% and +42.02%, respectively.
Any recent changes to analyst estimates for Eli Lilly should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.6% higher. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is presently being traded at a Forward P/E ratio of 42.22. This valuation marks a premium compared to its industry average Forward P/E of 14.09.
We can also see that LLY currently has a PEG ratio of 1.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.6 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 185, finds itself in the bottom 26% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.